Floatz logo

Pen-866

Gastroesophageal Junction Adenocarcinoma

Tarveda TherapeuticsPhase 1/2Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

113 Active assets in the Gastroesophageal Junction Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
AstraZeneca
Phase 3BBB
Cyclophosphamide
Beijing Biotech
Phase 3BB
Pembrolizumab
Eikon Therapeutics
Phase 3BB
FLUOROURACILUM
Alliance for Clinical Trials in Oncology
Phase 3BB
Eloxatin
Alliance for Clinical Trials in Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

Pen-866 is also rated in:

endometrium adenocarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
anal squamous cell carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
pancreatic adenocarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →